Гексаазоизовюрцитан - анальгетик нового поколения

Detaylı Bibliyografya
Parent link:Перспективы развития фундаментальных наук=Prospects of Fundamental Sciences Development: сборник научных трудов XV Международной конференции студентов, аспирантов и молодых ученых, г. Томск, 24-27 апреля 2018 г./ Национальный исследовательский Томский политехнический университет (ТПУ) ; под ред. И. А. Курзиной, Г. А. Вороновой.— , 2018
Т. 4 : Биология и фундаментальная медицина.— 2018.— [С. 99-101]
Yazar: Лопатина К. А.
Kurumsal yazarlar: Томский национальный исследовательский медицинский центр Российской академии наук, Научно-исследовательский институт фармакологии и регенеративной медицины имени Е. Д. Гольдберга
Diğer Yazarlar: Сафонова Е. А. (727), Рыбалкина О. Ю., Крылова С. Г.
Özet:Заглавие с экрана
The results of the expressed analgesic activity of the novel compound 4- (3,4dibromothiophenecarbonyl) -2,6,8,12-tetraacetyl-2,4,6,8,10,12 hexa-azatetracyclo [5,5,0,03,11, 05.9] dodecane (tioviurcin) were obtained under the conditions of the chemogenic activation model of the TRPA1 channel "formalin test" and in the selective test with agonist TRPV1 channels "Capsaicin test". It was found that tiovurcin in the preventive single intragastric administration via the probe at doses of 100 and 200 mg/kg effectively blocks nociceptive reactions caused by activation of TRPA1 and TRPV1 ion channels.
Baskı/Yayın Bilgisi: 2018
Konular:
Online Erişim:http://earchive.tpu.ru/handle/11683/50898
Materyal Türü: Elektronik Kitap Bölümü
KOHA link:https://koha.lib.tpu.ru/cgi-bin/koha/opac-detail.pl?biblionumber=627662
Diğer Bilgiler
Özet:Заглавие с экрана
The results of the expressed analgesic activity of the novel compound 4- (3,4dibromothiophenecarbonyl) -2,6,8,12-tetraacetyl-2,4,6,8,10,12 hexa-azatetracyclo [5,5,0,03,11, 05.9] dodecane (tioviurcin) were obtained under the conditions of the chemogenic activation model of the TRPA1 channel "formalin test" and in the selective test with agonist TRPV1 channels "Capsaicin test". It was found that tiovurcin in the preventive single intragastric administration via the probe at doses of 100 and 200 mg/kg effectively blocks nociceptive reactions caused by activation of TRPA1 and TRPV1 ion channels.